AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
teniposide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2590 | 29767-20-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.03 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 9 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 10.66 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 41 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.41 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.19 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 16 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.708 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 14.894 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 13.397 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 6.095 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 30.190 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 43.810 | % | High | 1 |
| herg | hERG pIC50 | 4.434 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.565 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 17.742 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 20.410 | % | High | 1 |
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,TEK,TGFBR1,ZAP70 | 34 | |||
| kinase-selectivity-class | GRK2,MAP2K6 | 2 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 9.683 | Moderate | 0.77 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 16.943 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 53.951 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 19.380 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 47.534 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.77 | |
| pppb | Pig plasma protein binding (% unbound) | 39.290 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.004 | % | Moderate | 0.77 |
| rh-clint | Rat hepatocyte intrinsic clearance | 37.325 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 77.810 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 13.870 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 153.109 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 14, 1992 | FDA | HQ SPECLT PHARMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ototoxicity | 380.81 | 124.90 | 55 | 506 | 4076 | 110584662 |
| Deafness | 166.27 | 124.90 | 36 | 525 | 26673 | 110562065 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01CB02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Podophyllotoxin derivatives |
| FDA MoA | N0000000176 | Topoisomerase Inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| FDA EPC | N0000175609 | Topoisomerase Inhibitor |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50750 | EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute lymphoid leukemia | indication | 91857003 | DOID:9952 |
| Follicular non-Hodgkin's lymphoma | off-label use | 308121000 | |
| Neuroblastoma | off-label use | 432328008 | DOID:769 |
| Viral disease | contraindication | 34014006 | DOID:934 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Bacterial infectious disease | contraindication | 87628006 | |
| Stupor | contraindication | 89458003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Bone marrow depression | contraindication | 307762000 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.96 | acidic |
| pKa2 | 12.56 | acidic |
| pKa3 | 13.37 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA topoisomerase 2-alpha | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| Multidrug resistance protein 1 | Transporter | WOMBAT-PK | |||||||
| ATP-binding cassette sub-family G member 2 | Transporter | WOMBAT-PK | |||||||
| Multidrug resistance-associated protein 6 | Transporter | WOMBAT-PK | |||||||
| Canalicular multispecific organic anion transporter 2 | Transporter | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4020571 | VUID |
| N0000148273 | NUI |
| D02698 | KEGG_DRUG |
| 4020571 | VANDF |
| C0039512 | UMLSCUI |
| CHEBI:75988 | CHEBI |
| 9TP | PDB_CHEM_ID |
| CHEMBL452231 | ChEMBL_ID |
| D013713 | MESH_DESCRIPTOR_UI |
| DB00444 | DRUGBANK_ID |
| 6843 | IUPHAR_LIGAND_ID |
| 3836 | INN_ID |
| 957E6438QA | UNII |
| 452548 | PUBCHEM_CID |
| 10362 | RXNORM |
| 203761 | MMSL |
| 5545 | MMSL |
| d01362 | MMSL |
| 003496 | NDDF |
| 387460005 | SNOMEDCT_US |
| 7959004 | SNOMEDCT_US |
Pharmaceutical products:
None